Quantcast
Home > Quotes > INFI
INFI

Infinity Pharmaceuticals, Inc. Common Stock (INFI) Quote & Summary Data

$1.65
*  
0.02
1.23%
Get INFI Alerts
*Delayed - data as of Jul. 18, 2019  -  Find a broker to begin trading INFI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    INFI After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.50 / $ 1.70
1 Year Target
3
Today's High / Low
$ 1.70 / $ 1.61
Share Volume
39,268
50 Day Avg. Daily Volume
84,074
Previous Close
$ 1.63
52 Week High / Low
$ 2.92 / $ 1
Market Cap
93,927,121
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.27
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.52

Intraday Chart

Shares Traded

Share Volume:
39,268
50 Day Avg. Daily Volume:
84,074

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.27

Trading Range

The current last sale of $1.65 is 65.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.70 $ 2.92
 Low: $ 1.61 $ 1

Company Description (as filed with the SEC)

We are an innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. We combine proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. We are focused on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma. We believe IPI-549 is the only clinical-stage selective inhibitor of PI3K-gamma currently being investigated. Selective inhibition of PI3K-gamma by IPI-549 targets tumor-associated myeloid cells, thereby reducing pro-tumor macrophage function and increasing anti-tumor macrophage function.  ... More ...  



Risk Grade

Where does INFI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.64
Open Date:
Jul. 18, 2019
Close Price:
$ 1.65
Close Date:
Jul. 18, 2019


Consensus Recommendation

Analyst Info